NASDAQ:QTTB Q32 Bio Q3 2026 Earnings Date & Estimates $8.65 -0.15 (-1.70%) Closing price 10/23/2026 04:00 PM EasternExtended Trading$8.36 -0.30 (-3.41%) As of 10/23/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Q32 Bio is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, before market opens. The conference call is scheduled for November 6, 2026 at 9:30 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 12, 2026TimeBefore Market OpensConference Call DateNovember 6, 2026Conference Call9:30 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Q32 Bio in Q3 2026Q32 Bio is expected to post earnings of -$0.36 per share. In the same quarter a year earlier Q32 Bio reported -$0.60 per share. Q32 Bio last reported on August 5, 2026, posting -$0.44 per share and beating the -$0.46 consensus estimate. Q32 Bio has beaten the consensus EPS estimate in 7 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.36Prior-Year EPS-$0.60Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.44 (Beat by +$0.02)EPS Beat Rate7 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Q32 Bio Q3 2026 Earnings FAQ When does Q32 Bio report Q3 2026 earnings? Q32 Bio (NASDAQ:QTTB) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Q32 Bio's Q3 2026 earnings call? Q32 Bio's Q3 2026 earnings conference call is scheduled for Friday, November 6, 2026 at 9:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Q32 Bio? Analysts expect Q32 Bio to post earnings of -$0.36 per share for Q3 2026. Q32 Bio Earnings HeadlinesLeerink Partners initiates coverage of Q32 Bio with outperformOctober 13, 2026 | msn.comJefferies Keeps Their Buy Rating on Q32 Bio (QTTB)October 3, 2026 | theglobeandmail.comYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strategy guide, titled How To Turn 100 Into 1000 Gains, before it moves behind a paywall. The guide walks through options trading concepts the team uses in its own research and education materials. Once the paywall goes up, free access ends for good.October 24 at 1:00 AM | TradeWins (Ad)Q32 Bio Reports Bempikibart Data In Alopecia AreataSeptember 30, 2026 | rttnews.comQ32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology ...September 30, 2026 | finance.yahoo.comQ32 Bio Sets 2027 Registration Program For Bempikibart In AlopeciaSeptember 30, 2026 | rttnews.comSee More Q32 Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Q32 Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Q32 Bio and other key companies, straight to your email. Email Address About Q32 BioQ32 Bio (NASDAQ:QTTB) (NASDAQ: QTTB) is a clinical-stage biotechnology company focused on developing biologic therapies for diseases associated with immune-system dysfunction. The company’s research programs are designed to restore immune balance rather than broadly suppress immune activity. Q32 Bio’s lead product candidate is bempikibart, formerly known as ADX-914, a fully human monoclonal antibody that targets activin receptor type IIA (ActRIIA). The company has evaluated bempikibart in inflammatory and autoimmune conditions, including atopic dermatitis and alopecia areata. The company also has pursued additional immunology programs, including therapies intended to address complement-mediated disease. Q32 Bio is headquartered in Waltham, Massachusetts, and its activities have primarily focused on advancing its pipeline through clinical development and regulatory evaluation. It does not have any widely marketed commercial products.View Q32 Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Lockheed Martin’s Record $292 Billion Backlog Comes With a Delivery TestSpotify Soars After Earnings as the Company Touts AI Benefits and Moderating CostsPalantir's Next Big Test Isn't a Partnership—It's the NumbersKinder Morgan's $4.7 Billion Pipeline Bet Could Be Bigger Than Its Earnings BeatCapital One Earnings: After a Double Beat the Rally Is OnTractor Supply's Q3 Beat Plants the Seeds for a Stock ReboundWD-40 Could Reward Patient Investors—Here's Why Upcoming Earnings Verizon Communications (10/26/2026)Nucor (10/26/2026)Public Storage (10/26/2026)Welltower (10/26/2026)Cadence Design Systems (10/26/2026)Hilton Worldwide (10/27/2026)Royal Caribbean Cruises (10/27/2026)CocaCola (10/27/2026)Coca Cola Femsa (10/27/2026)Baker Hughes (10/27/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
